58 Treatment of Chronic Hepatitis C With Telaprevir (Tvr) in Combination With Peginterferon-Alfa-2a With or Without Ribavirin: Further Interim Analysis Results of the Prove2 Study

Dusheiko, GM; Hézode, Christophe; Pol, Stanislas; Goeser, Tobias; Bronowicki, Jean–Pierre; Bourlière, Marc; Buggisch, Peter; Serfaty, Lawrence; Berg, Thomas; Couzige, P.; Benhamou, Yves; Forestier, Nicole; Bengtsson, Leif; Gharakhanian, Shahin; Kauffman, R. G.; Alam, Junaid Mahmood; Ferenci, Péter; Pawlotsky, Jean‐Michel; Zeuzem, Stefan

doi:10.1016/s0168-8278(08)60060-4

Cited by 38 publications

(35 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A similar trial in Europe achieved an SVR in 68% with the 24-week triple-drug regimen compared to 48% with standard treatment [Dusheiko et al 2008]. A lower dose or elimination of ribavirin resulted in a lower chance of response.…”

Section: Polyprotein Translation and Protein Processingmentioning

confidence: 90%

Review: Hepatitis C virus replication and potential targets for direct-acting agents

O’Leary

Davis

2010

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Abstract:We finally stand at the brink of novel, oral, direct-acting antivirals for the treatment of hepatitis C virus (HCV) infection. Basic science research has lead to a greater understanding of the viral life cycle and identified numerous potential targets for therapy. Early compounds were plagued by inconsistent in vivo activity and side effects that led to discontinuation of investigational efforts. However, several agents have now progressed to phase 2 human studies and two protease inhibitors have completed enrolment for their phase 3 clinical trials and look promising. Thus, while it appears that protease inhibitors will likely be the next available drugs for the treatment of HCV infection, the quest for additional therapeutic agents will continue. The future of HCV therapy lies in multidrug cocktails of several agents targeted against a variety of targets. In the near future these agents will be added to the current standard therapy consisting of pegylated interferon and ribavirin; however, the ultimate and probably realistic goal will be to develop multidrug oral regiments to replace the need for interferon.

show abstract

Section: Polyprotein Translation and Protein Processingmentioning

confidence: 90%

Review: Hepatitis C virus replication and potential targets for direct-acting agents

O’Leary

Davis

2010

Therap Adv Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Nedavno je zavšena treća faza ispitivanja lečenja HHC sa dodavanjem standardnoj terapiji (PEG IFN-α+RBV) trećeg leka sa direktnim dejstvom na HCV (direktni antivirusni agens, DAA), koji inhibiše proteazu HCV (telaprevir ili boceprevir). Trostruka terapija kod bolesnika sa G1 HCV (PEG IFN-α+RBV+telaprevir ili boceprevir) se pokazala veoma efikasnom i kod ranije nelečenih i kod bezuspešno lečenih bolesnika, ili bolesnika sa relapsom posle prestanka standardne terapije [3,[16][17][18]. Uskoro se očekuje odobravanje primene ovih lekova (telaprevir, boceprevir) za lečenje HHC kod bolesnika sa G1 HCV.…”

Section: Uvodunclassified

Savremena terapija hroničnog hepatitisa C: efikasnost i mogućnost predviđanja terapijskog odgovora

Bozic

Bojović

Đonić-Nenezić

et al. 2011

BII

View full text Add to dashboard Cite

1Klinika za infektivne i tropske bolesti Kliničkog centra Srbije, Beograd Uvod. Hepatitis C virus (HCV) je jedan od glavnih uzročnika hroničnog hepatitisa, ciroze jetre i hepatocelularnog karcinoma (HCC). Savremena terapija hroničnog hepatitisa C (HHC) podrazumeva primenu pegilovanog interferona alfa 2a ili 2b (PEG IFN-α2a ili PEG IFN-α2b) i ribavirina (RBV). Cilj rada je da se proceni efikasnost HCV terapije i faktora za predviđanje terapijskog odgovora. Rezultati. U grupi bolesnika sa HHC više je bilo muškaraca (59,3%), starijih od 40 godina (58,2%), sa visokim stepenom bazalne viremije (63%) i sa G1 (67%) HCV. Bridging fibroza i ciroza (F3, F4) su nađene kod 54 (27, 84%) bolesnika. Stabilan virusološki odgovor (SVR) je postignut kod 69,2%, relaps kod 11,9%, a bez odgovora na terapiju je bilo 19,8% bolesnika. Faktori koji su uticali na postizanje SVR bili su: non-1 genotip HCV (OR 5,9; 95% IP: 1,9-18,0), EVR (OR 0,92,; 95% IP: 2,73-35,97) i bolesnici mlađi od 40 godina (OR 3,66; 95% IP: 1,48-9,0). Neuspeh terapije u vidu relapsa zavisio je od visine bazalne viremije (OR 0,37; 95% IP: 0,12-0,97), godina života >40 godina (OR 4,8; 95% IP: 1,35-17,84) i prisustva ciroze (OR 2,1; 95% IP: 1,0-4,7). Kod bolesnika bez odgovora na terapiju faktori predviđanja neuspeha su bili: G1 (OR 3,9; 95% IP: 1,5-10,3), visoka bazalna viremija (OR 3,45; 95% IP: 1,19) i prekid u kontinuitetu primene terapije (OR 4,49; 95% IP: 1,76).Zaključak. Savremena, standardna terapija je bila efikasna kod 127/194 (69,2%) bolesnika sa HCC. Najznačajniji faktori za predviđanje uspeha terapije bili su: genotip HCV, EVR kod G1, životno doba bolesnika, stepen bazalne viremije, prisustvo ciroze i prekid u kontinuitetu terapije.Ključne reči: hronični hepatitis C, efikasnost antivirusne terapije, predviđanje virusološkog odgovora.

show abstract

“…Two phase II trials, PROVE1 and PROE2, have been independently conducted [23,24]. In PROVE 1, 61% achieved SVR by the triple combination therapy for 24 weeks and 67% for 48 weeks, while only 41% achieved SVR standard of care treatment [25].…”

Section: Protease Inhibitorsmentioning

confidence: 99%

“…In PROVE 1, 61% achieved SVR by the triple combination therapy for 24 weeks and 67% for 48 weeks, while only 41% achieved SVR standard of care treatment [25]. In PROVE 2, 68 and 62% achieved SVR by 12-or 24-week triple combination therapy, while 48% achieved standard of care [24]. The above results from the two trials showed that treatment period of 24 weeks is sufficient to improve the outcome of the triple combination by over 20% compared to the conventional 48-week peginterferon and ribavirin treatment and that the combination with ribavirin is necessary to achieve optimal results.…”

Section: Protease Inhibitorsmentioning

confidence: 99%

See 1 more Smart Citation

New therapeutic approaches to hepatitis C virus

Sakamoto

Watanabe

2009

J Gastroenterol

View full text Add to dashboard Cite

Year 201X will see a huge battle against hepatitis C virus (HCV) infection. HCV, a leading cause of end stage diseases and hepatocellular malignancies, is a negative legacy of the past in many regions worldwide, and has long been refractory to conventional treatments. The most effective peginterferons and ribavirin-based antiviral therapies can eliminate the virus in only half of patients treated, and the treatments are often poorly tolerated. Recently, the development of an HCV cell culture system has become a turning point of basic research. At present, novel therapeutic agents with different mechanisms of action are under development or on clinical trials. Some of these drugs have been proven to be effective when used with the conventional treatments, and may constitute antiviral therapies without being used in combination with interferons. This article reviews the current status of preclinical drug development, ongoing clinical trials, and near future perspectives in the field of HCV therapeutics.

show abstract

58 Treatment of Chronic Hepatitis C With Telaprevir (Tvr) in Combination With Peginterferon-Alfa-2a With or Without Ribavirin: Further Interim Analysis Results of the Prove2 Study

Cited by 38 publications

References 0 publications

Review: Hepatitis C virus replication and potential targets for direct-acting agents

Review: Hepatitis C virus replication and potential targets for direct-acting agents

Savremena terapija hroničnog hepatitisa C: efikasnost i mogućnost predviđanja terapijskog odgovora

New therapeutic approaches to hepatitis C virus

Contact Info

Product

Resources

About